SINGAPORE – The days of blockbuster drugs may be coming to an end, but Harish Dave, chief medical officer at Singapore-based Aum Biosciences Pte. Ltd., offered companies a new term. During the second day of the Phar-East Pharma and Biotech Festival biopharma conference, Dave said companies should focus on "niche-busters" and finding new sectors to dominate instead.